2026 Interim Report
Filed with HKEX · Stock code 6998 · · 109 pages · English
CORPORATE INFORMATION 2 FINANCIAL HIGHLIGHTS 4 BUSINESS HIGHLIGHTS 5 MANAGEMENT DISCUSSION AND ANALYSIS 13 OTHER INFORMATION 26 REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION 75 INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS 76 INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 77 INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 78 INTERIM CONDENSED CONSO
Edding Genor Group Holdings Limited on 6ix
Earlier from Edding Genor
- EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA
- Edding Genor Group Holdings: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial
- Releases Its Interim Results for 2023
Later from Edding Genor
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Voluntary announcement - IND approval from the NMPA for Phase II clinical trial of GB268 in colorectal cancer
Follow Edding Genor into a list and get an email when it puts out news.
Follow Edding Genor